Bilinski A, Neumann P, Cohen J, Thorat T, McDaniel K, Salomon JA (2017) When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. PLoS Med 14 (10): e1002397 [PLOS Medicine]

Cohen JT, Neumann PJ, Wong JB. A Call for Open-Source Cost-Effectiveness Analysis. Annals of Internal Medicine. August 29, 2017. Epub ahead of print [PubMed]

Cohen JT, Wong JB.  Can economic model transparency improve provider interpretation of cost-effectiveness analysis?  A response.  Med Care 2017;55(11):912–914   

Emerson J, Panzer A, Cohen JT, et al.  Adherence to the iDSI reference case among published cost-per-DALY averted studies.  [PLoS ONE] 2019;14(5): e0205633.

Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value in Health 2018;21(7):759–61 [Value in Health]

Neumann PJ, Anderson JE, Panzer AD et al. Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures [version 2; referees: 3 approved]. Gates Open Res 2018, 2:5 [Gates Open Research]

Neumann PJ, Thorat T, Zhong Y, Anderson JE, Farquhar M, Salem M, Sandberg E, Saret CJ, Wilkinson C, Cohen JT. A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. PLoS One. 2016; 11(12): e0168512 [PubMed]

Teerawattananon Y, Tantivess S, Yamabhai I, Tritasavit N, Walker DG, Cohen JT, Neumann PJ. The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. Health Research Policy and Systems, 2016 [PubMed]

Technical Reports:

Emerson, J. and Kim, D.D. (2018). Disability-Adjusted Life Year Conversion, Case Study #1: HIV Cases to DALYs. Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA  [Link to download]